EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Research progress of exosomes in renal ischemia-reperfusion injury

Supeng Tai, Weibo Wang, Guangyue Luo, Junyue Tao, Chaozhao Liang, Jun Zhou

Frontiers in Pharmacology · 12.05.2026 · 17

DOI: 10.3389/fphar.2026.1763241 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 12.05.2026. Verfasst von Supeng Tai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal ischemia-reperfusion injury (RIRI), which causes renal damage that occurs when blood flow is restored after a period of reduced perfusion, is a common cause of acute kidney injury. As the disease progresses, treatment options become increasingly limited, highlighting the urgent need for new therapeutic approaches. Among these, exosomes (Exos) have shown great potential in the prevention and treatment of this condition. Exos are nano-sized vesicles of endosomal origin, typically less than 200 nm in diameter, and have emerged as key mediators in diverse pathophysiological processes. This article provides a comprehensive narrative review of the mechanisms of various types of Exos in renal ischemia-reperfusion injury and the advancements in exosome therapy, and details both their renoprotective mechanisms and potential pathogenic effects. Furthermore, we highlight advanced bioengineering strategies, delivery platforms, and diagnostic potential. By explicitly addressing translational barriers and the need for rigorous methodological standardization, we aim to provide comprehensive insights for advancing exosome-based RIRI management from bench to clinic.

Schlagwörter

Stichwörter der Autor:innen

drug deliveryexosomehydrogelsprogrammed cell deathrenal ischemia-reperfusion injury

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Institute of Urology, Anhui Medical University, Hefei, Anhui, China.
  • Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei, Anhui, China.

Zitieren

APA

Tai, S., Wang, W., Luo, G., Tao, J., Liang, C., & Zhou, J. (2026). Research progress of exosomes in renal ischemia-reperfusion injury. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1763241

Vancouver

Tai S, Wang W, Luo G, Tao J, Liang C, Zhou J. Research progress of exosomes in renal ischemia-reperfusion injury. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1763241

BibTeX
@article{Tai2026,
  author = {Tai, Supeng and Wang, Weibo and Luo, Guangyue and Tao, Junyue and Liang, Chaozhao and Zhou, Jun},
  title = {Research progress of exosomes in renal ischemia-reperfusion injury},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1763241}
}
Kostenlos starten →